Limbal Stem Cell Deficiency: Current Treatment Options and Emerging Therapies.
Limbal Stem Cell Deficiency: Current Treatment Options and Emerging Therapies.
复制标题
DOI：
10.1155/2016/9798374
复制
发表时间：
2016
影响因子：
4.3
通讯作者：
Zakaria N
中科院分区：
文献类型：
--
作者：
Haagdorens M;Van Acker SI;Van Gerwen V;Ní Dhubhghaill S;Koppen C;Tassignon MJ;Zakaria N
严重的眼表疾病可导致角膜缘干细胞缺乏症（LSCD），这种疾病会导致视力下降、畏光和眼痛。为了修复晚期干细胞缺损角膜的眼表，需要进行自体或异体角膜缘干细胞移植。近年来，通过优化培养角膜缘上皮移植（CLET），大角膜缘移植物切除后继发LSCD的风险显著降低。尽管CLET取得了巨大的成功，但仍有改进的余地，因为移植成功后的总体成功率为70%，视力通常仍处于次优状态。简单的角膜缘上皮移植成功率较高，但尚未在许多患者中进行。本文就角膜缘上皮干细胞及LSCD的病理生理机制作一综述。本文描述了LSCD的最新治疗管理，并讨论了眼表再生的新技术和发展中的技术，特别是基于细胞的眼表重建的替代细胞支架和细胞来源的优缺点。
Severe ocular surface disease can result in limbal stem cell deficiency (LSCD), a condition leading to decreased visual acuity, photophobia, and ocular pain. To restore the ocular surface in advanced stem cell deficient corneas, an autologous or allogenic limbal stem cell transplantation is performed. In recent years, the risk of secondary LSCD due to removal of large limbal grafts has been significantly reduced by the optimization of cultivated limbal epithelial transplantation (CLET). Despite the great successes of CLET, there still is room for improvement as overall success rate is 70% and visual acuity often remains suboptimal after successful transplantation. Simple limbal epithelial transplantation reports higher success rates but has not been performed in as many patients yet. This review focuses on limbal epithelial stem cells and the pathophysiology of LSCD. State-of-the-art therapeutic management of LSCD is described, and new and evolving techniques in ocular surface regeneration are being discussed, in particular, advantages and disadvantages of alternative cell scaffolds and cell sources for cell based ocular surface reconstruction.